Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Novel Genome Editing for the Treatment of Glaucoma

Award Number: R01EY030366
ORGANIZATION: NATIONAL EYE INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2019
PERIOD OF PERFORMANCE END DATE: 04/30/2025

Group Awards By:

View Award Description

Novel Genome Editing for the Treatment of Glaucoma - Abstract Glaucoma is a heterogenous group of optic neuropathies and a leading cause of irreversible vision loss and blindness worldwide. Primary Open Angle Glaucoma (POAG) is the most common form of glaucoma and is often associated with elevated intraocular pressure (IOP), a leading causative risk factor for glaucoma. Elevated IOP is due to damage to the trabecular meshwork (TM) that increases resistance to aqueous humor outflow. Current glaucoma treatments do not address the underlying primary pathophysiological mechanisms and the disorder can continue to progress despite treatment. To truly cure glaucoma, there is critical need to permanently inhibit or reverse the glaucomatous damage to the TM and restore normal TM cell functions. New technologies, specifically CRISPR/Cas9 genome editing, allow investigators to directly modify the genes associated with pathogenic damage. We recently demonstrated the feasibility of targeting the mutant myocilin gene using CRISPR-Cas9 genome editing to prevent and reverse glaucoma in myocilin-associated POAG in mice and in human donor eyes. It is our goal to develop genome editing methods targeting the TM for the treatment of myocilin-associated POAG, and importantly the treatment of POAG in general. We have a unique opportunity to cure glaucoma by inhibiting the ongoing disease pathology by targeting common pathological pathways associated with general POAG. We have previously linked the pathological role of endoplasmic reticulum (ER) stress to the glaucomatous TM damage and IOP elevation in mouse models of ocular hypertension and in human donor eyes. Specifically, we have shown that ER-stress induced ATF4 and CHOP are associated with glaucomatous TM damage and independent inhibition of ATF4 and CHOP can be a novel treatment strategy for general POAG. Therefore, we propose to target this common underlying mechanism using the CRISPR-Cas9 system. It is our overall goal to design AAV vectors encoding CRISPR/Cas9 targeting MYOC, CHOP and ATF4 to selectively knockout these genes in the TM and lower IOP in mouse ocular hypertension models, as well as in ex vivo human perfusion organ cultured anterior segments. We hypothesize that genome editing knockout of MYOC, CHOP and ATF4 using AAV.CRISPR/Cas9 vectors targeting the TM will prevent and reverse elevated IOP in glaucoma. We will use AAV vectors because these agents have been used for gene therapy in patients with specific eye diseases. In this proposal, we will first determine the most efficient AAV vector(s) for TM tropism and design efficient CRISPR/Cas9 constructs that effectively knockdown MYOC, CHOP and ATF4 in the TM. We will also evaluate CRISPR-Cas9 off-target effects in human donor eyes. Second, we determine the efficacy of AAV.cr. MYOC, AAV.cr. CHOP and AAV.cr. ATF4 knockouts in the TM and the ability of these knockouts to reduce elevated IOP in vivo in mice and ex vivo in human perfusion organ cultured anterior segments. Our approach will revolutionize glaucoma therapy by directly interfering with glaucomatous damage to the TM and provide a one-time therapy to effectively treat glaucoma resulting from elevated IOP.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = -$936 )
2025	2023	THE UNIVERSITY OF IOWA	105 JESSUP HALL	IOWA CITY	IA	52242	JOHNSON	USA	Vision Research	000	5	7/22/2025	NON-COMPETING CONTINUATION	-$936
														Subtotal = -$936

Issue Date FY: 2023 ( Subtotal = $622,736 )
2023	2023	THE UNIVERSITY OF IOWA	105 JESSUP HALL	IOWA CITY	IA	52242	JOHNSON	USA	Vision Research	001	5	6/2/2023	NON-COMPETING CONTINUATION	$473,396
2023	2023	THE UNIVERSITY OF IOWA	105 JESSUP HALL	IOWA CITY	IA	52242	JOHNSON	USA	Vision Research	000	4	3/8/2023	SUPPLEMENT FOR EXPANSION	$149,340
														Subtotal = $622,736

Issue Date FY: 2022 ( Subtotal = $459,195 )
2022	2022	UNIVERSITY OF IOWA, THE	105 JESSUP HALL	IOWA CITY	IA	52242	JOHNSON	USA	Vision Research	001	4	5/25/2022	NON-COMPETING CONTINUATION	$63,734
2022	2022	UNIVERSITY OF IOWA, THE	105 JESSUP HALL	IOWA CITY	IA	52242	JOHNSON	USA	Vision Research	000	4	4/25/2022	NON-COMPETING CONTINUATION	$395,461
														Subtotal = $459,195

Issue Date FY: 2021 ( Subtotal = $527,925 )
2021	2021	UNIVERSITY OF IOWA, THE	105 JESSUP HALL	IOWA CITY	IA	52242	JOHNSON	USA	Vision Research	000	3	4/15/2021	NON-COMPETING CONTINUATION	$527,925
														Subtotal = $527,925

Issue Date FY: 2020 ( Subtotal = $548,796 )
2020	2020	UNIVERSITY OF IOWA, THE	105 JESSUP HALL	IOWA CITY	IA	52242	JOHNSON	USA	Vision Research	001	2	9/2/2020	SUPPLEMENT FOR EXPANSION	$70,857
2020	2020	UNIVERSITY OF IOWA, THE	105 JESSUP HALL	IOWA CITY	IA	52242	JOHNSON	USA	Vision Research	000	2	4/27/2020	NON-COMPETING CONTINUATION	$477,939
														Subtotal = $548,796

Issue Date FY: 2019 ( Subtotal = $491,564 )
2019	2019	UNIVERSITY OF IOWA, THE	105 JESSUP HALL	IOWA CITY	IA	52242	JOHNSON	USA	Vision Research	000	1	6/18/2019	NEW	$491,564
														Subtotal = $491,564

Grand Total All Awards = $2,649,280

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Novel Genome Editing for the Treatment of Glaucoma

Award Number: R01EY030366

ORGANIZATION: NATIONAL EYE INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2019

PERIOD OF PERFORMANCE END DATE: 04/30/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer